Signing of definitive purchase agreement represents critical next step in completing previously announced acquisitionSARASOTA, Fla. and INDIANAPOLIS, Dec. 17, 2025...
Signing of definitive purchase agreement represents critical next step in completing previously announced acquisitionSARASOTA, Fla. and INDIANAPOLIS, Dec. 17, 2025...
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics...
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics...
FRAMINGHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global advisory firm and CRO, today announced the appointment...
FRAMINGHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global advisory firm and CRO, today announced the appointment...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s...
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated...
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated...
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel...
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel...
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all...
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all...
COSTA MESA, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- TadHealth, a leading provider of school-based mental health technology, has been...
COSTA MESA, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- TadHealth, a leading provider of school-based mental health technology, has been...
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for...
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for...
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track...
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track...